This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Recurrent Acute Myeloid Leukemia or Refractory Acute Myeloid Leukemia
and you are
over 18
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This phase I trial studies the side effects and best dose of oxidative phosphorylation inhibitor IACS-010759 in treating patients with acute myeloid leukemia that has come back or does not respond to treatment. Oxidative phosphorylation inhibitor IACS-010759 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Provided treatments

  • Drug: Oxidative Phosphorylation Inhibitor IACS-010759
  • Other: Pharmacological Study

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02882321. The sponsor of the trial is M.D. Anderson Cancer Center and it is looking for 23 volunteers for the current phase.
Official trial title:
Phase 1 Study of IACS-010759 in Subjects With Relapsed or Refractory AML